Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry

Frontiers in Medicine

Volumn 1, Issue NOV, 2014, Pages

  Watering, Floor C J van de ^a   Rijpkema, Mark ^a   Robillard, Marc ^b   Oyen, Wim J G ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Tagworks Pharmaceuticals   (Netherlands)

Author keywords

Bispecific antibodies; Pretargeting; Radioimmunodetection; Radioimmunotherapy; Tumor associated antigen

Indexed keywords

EID: 85061988238     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00044     Document Type: Review

References (66)

1. Fleuren EDG, Versleijen-Jonkers YMH, Heskamp S, van Herpen CML, Oyen WJG, van der Graaf WTA, et al. Theranostic applications of antibodies in oncology. Mol Oncol (2014) 8(4):799-812. doi: 10.1016/j.molonc.2014.03.010
2. Heskamp S, van Laarhoven HW, Oyen WJ, van der Graaf WT, Boerman OC. Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. Curr Mol Med (2013) 13(10):1506-22. doi:10.2174/1566524013666131111120638
3. Goldenberg DM, Sharkey RM. Using antibodies to target cancer therapeutics. Expert Opin Biol Ther (2012) 12(9):1173-90. doi:10.1517/14712598.2012.693472
4. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 44(3):400-11
5. Kong F-L, Ford RJ, Yang DJ. Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications. Biomed Res Int (2013) 2013:12. doi:10.1155/2013/626910
6. Sharkey R, Chang C-H, Rossi E, McBride W, Goldenberg D. Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biol (2012) 33(3):591-600. doi:10.1007/s13277-012-0367-6
7. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med (1987) 28(8):1294-302
8. Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, et al. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther (2010) 10(8):767-74. doi:10.4161/cbt.10.8.12879
9. Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, et al. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging (2010) 54(3):333-40
10. He J, Wang Y, Dou S, Liu X, Zhang S, Liu G, et al. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF. Mol Pharm (2010) 7(4):1118-24. doi:10.1021/mp9002909
11. He J, Liu G, Gupta S, Zhang Y, Rusckowski M, Hnatowich DJ. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. J Nucl Med (2004) 45(6):1087-95
12. Carroll L, Evans HL, Aboagye EO, Spivey AC. Bioorthogonal chemistry for pre-targeted molecular imaging-progress and prospects. Org Biomol Chem (2013) 11(35):5772-81. doi:10.1039/c3ob40897c
13. King M, Wagner A. Developments in the field of bioorthogonal bond forming reactions-past and present trends. Bioconjug Chem (2014) 25(5):825-39. doi:10.1021/bc500028d
14. Förster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med (2006) 47(1):140-9
15. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, et al. Antibodies against metal chelates. Nature (1985) 316(6025):265-8. doi:10.1038/316265a0
16. Boerman OC, Kranenborg MHGC, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJG, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res (1999) 59(17):4400-5
17. Primus FJ, Wang RH, Goldenberg DM, Hansen HJ. Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res (1973) 33(11):2977-82
18. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res (1989) 37(1):77-104. doi:10.1016/0026-2862(89)90074-5
19. Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res (1991) 51(24):6650-5
20. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1(7):553-63
21. Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies:? role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem (2002) 13(5):1054-70. doi:10.1021/bc0200172
22. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med (1989) 30(8):1358-66
23. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res (1990) 50(11):3445-52
24. Kraeber-Bodere F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res (1999) 5(10 Suppl):3190s-8s
25. Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med (1998) 39(7):1172-8
26. Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res (1994) 54(22):5937-46
27. Le Doussal JM, Barbet J, Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. Int J Cancer Suppl (1992) 7:58-62
28. Le Doussal JM, Gautherot E, Martin M, Barbet J, Delaage M. Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails. J Immunol (1991) 146(1):169-75
29. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, Martin M, Gautherot E, Lehur PA, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med (1993) 34(10):1662-71
30. Bardies M, Bardet S, Faivre-Chauvet A, Peltier P, Douillard JY, Mahe M, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med (1996) 37(11):1853-9
31. Doussal J-ML, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of Indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res (1990) 50(11):3445-52
32. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 63(2):354-63
33. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, Cohen M, Milhaud G, Tartar A, et al. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem (1997) 8(4):526-33. doi:10.1021/bc970083h
34. Hosono M, Hosono MN, Kraeber-Bodere F, Devys A, Thedrez P, Faivre-Chauvet A, et al. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med (1999) 40(7):1216-21
35. McBride WJ, Zanzonico P, Sharkey RM, Noren C, Karacay H, Rossi EA, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med (2006) 47(10):1678-88
36. Griffiths GL, Chang CH, McBride WJ, Rossi EA, Sheerin A, Tejada GR, et al. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med (2004) 45(1):30-9
37. Karacay H, Sharkey RM, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga. J Nucl Med (2011) 52(4):555-9. doi:10.2967/jnumed.110.083568
38. McBride WJ, D'Souza CA, Sharkey RM, Goldenberg DM. The radiolabeling of proteins by the [18F]AlF method. Appl Radiat Isot (2012) 70(1):200-4. doi:10.1016/j.apradiso.2011.08.013
39. Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBride W, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res (2005) 11(19 Pt 2):7122s-9s. doi:10.1158/1078-0432.CCR-1004-0020
40. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 103(18):6841-6. doi:10.1073/pnas.0600982103
41. Chang C-H, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res (2007) 13(18):5586s-91s. doi:10.1158/1078-0432.CCR-07-1217
42. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2008) 49(1):158-63. doi:10.2967/jnumed.107.046185
43. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, et al. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology (2008) 246(2):497-507. doi:10.1148/radiol.2462070229
44. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res (2005) 11(21):7879-85. doi:10.1158/1078-0432.CCR-05-1246
45. van Rij CM, Lutje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 40(9):1377-83. doi:10.1007/s00259-013-2434-7
46. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang C-H, et al. Improved therapeutic results by pretargeted radioimmunotherapy of Non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res (2008) 68(13):5282-90. doi:10.1158/0008-5472.CAN-08-0037
47. Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang C-H, Modrak DE, et al. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res (2004) 10(10):3552-61. doi:10.1158/1078-0432.CCR-03-0340
48. Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, et al. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga-and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 9(4):1019-27. doi:10.1158/1535-7163.MCT-09-0862
49. Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, et al. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res (2012) 2:5. doi:10.1186/2191-219X-2-5
50. Schoffelen R, van der Graaf WTA, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med (2010) 51(11):1780-7. doi:10.2967/jnumed.110.079376
51. Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, et al. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J Nucl Med (2012) 53(12):1926-32. doi:10.2967/jnumed.112.106278
52. Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer (2013) 109(4):934-42. doi:10.1038/bjc.2013.376
53. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer (2012) 118(22):5497-506. doi:10.1002/cncr.27592
54. Sletten EM, Bertozzi CR. From mechanism to mouse: a tale of two bioorthogonal reactions. Acc Chem Res (2011) 44(9):666-76. doi:10.1021/ar200148z
55. Borrmann A, van Hest JCM. Bioorthogonal chemistry in living organisms. Chem Sci (2014) 5(6):2123-34. doi:10.1039/c3sc52768a
56. Reiner T, Zeglis BM. The inverse electron demand Diels-Alder click reaction in radiochemistry. J Labelled Comp Radiopharm (2014) 57(4):285-90. doi:10.1002/jlcr.3149
57. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed (2001) 40(11):2004-21. doi:10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5
58. Gill HS, Marik J. Preparation of 18F-labeled peptides using the copper(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition. Nat Protoc (2011) 6(11):1718-25. doi:10.1038/nprot.2011.390
59. Devaraj NK, Upadhyay R, Haun JB, Hilderbrand SA, Weissleder R. Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed (2009) 48(38):7013-6. doi:10.1002/anie.200903233
60. Rossin R, Verkerk PR, van den Bosch SM, Vulders RC, Verel I, Lub J, et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew Chem Int Ed Engl (2010) 49(19):3375-8. doi:10.1002/anie.201001645
61. Rossin R, van den Bosch SM, ten Hoeve W, Carvelli M, Versteegen RM, Lub J, et al. Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems. Bioconjug Chem (2013) 24(7):1210-7. doi:10.1021/bc400153y
62. van den Bosch SM, Rossin R, Renart Verkerk P, Ten Hoeve W, Janssen HM, Lub J, et al. Evaluation of strained alkynes for Cu-free click reaction in live mice. Nucl Med Biol (2013) 40:415-23. doi:10.1016/j.nucmedbio.2012.12.006
63. Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, et al. A pretargeted PET imaging strategy based on bioorthogonal diels-alder click chemistry. J Nucl Med (2013) 54(8):1389-96. doi:10.2967/jnumed.112.115840
64. Devaraj NK, Thurber GM, Keliher EJ, Marinelli B, Weissleder R. Reactive polymer enables efficient in vivo bioorthogonal chemistry. Proc Natl Acad Sci U S A (2012) 109(13):4762-7. doi:10.1073/pnas.1113466109
65. Rossin R, van Duijnhoven SM, Läppchen T, van den Bosch SM, Robillard MS. Trans-cyclooctene tag with improved properties for tumor pretargeting with the Diels-Alder reaction. Mol Pharm (2014) 11(9):3090-6. doi:10.1021/mp500275a
66. Lee SB, Kim HL, Jeong H-J, Lim ST, Sohn M-H, Kim DW. Mesoporous silica nanoparticle pretargeting for pet imaging based on a rapid bioorthogonal reaction in a living body. Angew Chem Int Ed Engl (2013) 52(40):10549-52. doi:10.1002/anie.201304026